GPX4 and neoplasm: Additionally, tumor cells with mutations in isocitrate dehydrogenase 1 (IDH1) undergo metabolic changes, leading to elevated levels of 2-hydroxyglutarate (2-HG), which inhibits the activity of GPX4, promoting the accumulation of intracellular ROS (72).